Immunotherapy of Brain Cancer

Oncology Research and Treatment

Volumn 39, Issue 6, 2016, Pages 326-334

  Roth, Patrick ^a   Preusser, Matthias ^b   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Brain metastasis; Brain tumor; Checkpoint inhibition; CTLA 4; Glioblastoma; Nivolumab; PD 1; Pembrolizumab; Vaccination

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TETANUS TOXOID; DURVALUMAB; IMA 950; INDOXIMOD; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RINDOPEPIMUT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BRAIN METASTASIS; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CHEMORADIOTHERAPY; EFFECTOR CELL; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTERNALIZATION; MELANOMA; METASTATIC MELANOMA; MICROGLIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BRAIN NEOPLASMS; EVIDENCE BASED MEDICINE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84970028919     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000446338     Document Type: Review

References (66)

1. Ransohoff RM, Engelhardt B: The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012; 12: 623-635.
2. D'Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K: Brain dendritic cells: Biology and pathology. Acta Neuropathol 2012; 124: 599-614.
3. Roth P, Regli L, Tonder M, Weller M: Tumor-associated edema in brain cancer patients: Pathogenesis and management. Expert Rev Anticancer Ther 2013; 13: 1319-1325.
4. Ciccarelli O, Barkhof F, Bodini B, et al.: Pathogenesis of multiple sclerosis: Insights from molecular and metabolic imaging. Lancet Neurol 2014; 13: 807-822.
5. Louveau A, Smirnov I, Keyes TJ, et al.: Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337-341.
6. Schlager C, Korner H, Krueger M, et al.: Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 2016; 530: 349-353.
7. Berghoff AS, Fuchs E, Ricken G, et al.: Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 2016; 5:e1057388.
8. Guirguis LM, Yang JC, White DE, et al.: Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002; 25: 82-87.
9. Chu MB, Fesler MJ, Armbrecht ES, et al.: High-dose interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother Res Pract 2013; 2013: 726925.
10. Roth P, Eisele G, Weller M: Immunology of brain tumors. Handb Clin Neurol 2012; 104: 45-51.
11. Frei K, Gramatzki D, Tritschler I, et al.: Transforming growth factor-beta pathway activity in glioblastoma. Oncotarget 2015; 6: 5963-5977.
12. Roth P, Junker M, Tritschler I, et al.: GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010; 16: 3851-3859.
13. Codo P, Weller M, Meister G, et al.: MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget 2014; 5: 7651-7662.
14. Roth P, Mittelbronn M, Wick W, et al.: Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 2007; 67: 3540-3544.
15. Hishii M, Nitta T, Ishida H, et al.: Human gliomaderived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37: 1160-1166;discussion 1166-1167.
16. Lauro GM, Di Lorenzo N, Grossi M, et al.: Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol 1986; 69: 278-282.
17. Grauer OM, Nierkens S, Bennink E, et al.: CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95-105.
18. Rodon J, Carducci MA, Sepulveda-Sanchez JM, et al.: First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res 2015; 21: 553-560.
19. Brandes AA, Carpentier AF, Kesari S, et al.: A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol 2016;[Epub ahead of print].
20. Platten M, Wick W, Van den Eynde BJ: Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res 2012; 72: 5435-5440.
21. Wainwright DA, Balyasnikova IV, Chang AL, et al.: IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012; 18: 6110-6121.
22. Zhai L, Lauing KL, Chang AL, et al.: The role of IDO in brain tumor immunotherapy. J Neurooncol 2015; 123: 395-403.
23. Zakharia Y, Johnson TS, Colman H, Vahanian NN: A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomiderefractory primary malignant brain tumors. J Clin Oncol 2014; 32: 5s.
24. Buchbinder E, Hodi FS: Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125: 3377-3383.
25. Preusser M, Lim M, Hafler DA, et al.: Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 2015; 11: 504-514.
26. Belcaid Z, Phallen JA, Zeng J, et al.: Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS One 2014; 9:e101764.
27. Reardon DA, Gokhale PC, Klein SR, et al.: Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 2016; 4: 124-135.
28. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
29. Margolin K, Ernstoff MS, Hamid O, et al.: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
30. Di Giacomo AM, Ascierto PA, Pilla L, et al.: Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial. Lancet Oncol 2012; 13: 879-886.
31. Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, et al.: Ipilimumab in melanoma patients with brain metastasis: A retro-spective multicentre evaluation of thirtyeight patients. Acta Derm Venereol 2014; 94: 45-49.
32. Silk AW, Bassetti MF, West BT, et al.: Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2: 899-906.
33. Tazi K, Hathaway A, Chiuzan C, Shirai K: Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015; 4: 1-6.
34. Kiess AP, Wolchok JD, Barker CA, et al.: Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92: 368-375.
35. Berghoff AS, Ricken G, Widhalm G, et al.: Tumourinfiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015; 66: 289-299.
36. Harter PN, Bernatz S, Scholz A, et al.: Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 2015; 6: 40836-40849.
37. Robert C, Long GV, Brady B, et al.: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
38. Robert C, Ribas A, Wolchok JD, et al.: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
39. Rothermundt C, Hader C, Gillessen S: Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol 2016; 27: 544-545.
40. Kluger HM, Goldberg SB, Sznol M, et al.: Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol 2015; 33 (suppl, abstr 9009).
41. Rizvi NA, Mazieres J, Planchard D, et al.: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-265.
42. Goldberg SB, Gettinger SN, Mahajan A, et al.: Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol 2015; 33 (suppl; abstr 8035).
43. Ahmed KA, Stallworth DG, Kim Y, et al.: Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2016; 27: 434-441.
44. Berghoff AS, Kiesel B, Widhalm G, et al.: Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015; 17: 1064-1075.
45. Nduom EK, Wei J, Yaghi NK, et al.: PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 2016; 18: 195-205.
46. Sampson JH, Vlahovic G, Sahebjam S, et al.: Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): Checkmate-143. J Clin Oncol 2015; 33 (suppl; abstr 3010).
47. Chiang CL, Coukos G, Kandalaft LE: Whole tumor antigen vaccines: Where are we? Vaccines (Basel) 2015; 3: 344-372.
48. Reardon DA, Wucherpfennig KW, Freeman G, et al.: An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines 2013; 12: 597-615.
49. Sampson JH, Aldape KD, Archer GE, et al.: Greater chemotherapy-induced lymphopenia enhances tumorspecific immune responses that eliminate EGFRvIIIexpressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13: 324-333.
50. Sampson JH, Heimberger AB, Archer GE, et al.: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-4729.
51. Schuster J, Lai RK, Recht LD, et al.: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. Neuro Oncol 2015; 17: 854-861.
52. Reardon DA, Schuster J, Tran DD, Fink KL: ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 2015; 33(suppl; abstr 2009).
53. Johnson BF, Clay TM, Hobeika AC, et al.: Vascular endothelial growth factor and immunosuppression in cancer: Current knowledge and potential for new therapy. Expert Opin Biol Ther 2007; 7: 449-460.
54. Voron T, Colussi O, Marcheteau E, et al.: VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139-148.
55. Hashimoto N, Tsuboi A, Kagawa N, et al.: Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: Safety and impact on immunological response. Cancer Immunol Immunother 2015; 64: 707-716.
56. Schumacher T, Bunse L, Pusch S, et al.: A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512: 324-327.
57. Okada H, Butterfield LH, Hamilton RL, et al.: Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptidebased vaccines in combination with poly-ICLC. Clin Cancer Res 2015; 21: 286-294.
58. Pollack IF, Jakacki RI, Butterfield LH, et al.: Antigenspecific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014; 32: 2050-2058.
59. Phuphanich S, Wheeler CJ, Rudnick JD, et al.: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62: 125-135.
60. Wen PY, Reardon DA, Phuphanich S, Aitken R: A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J Clin Oncol 2014; 32: 5s(suppl; abstr 2005).
61. Weiss T, Weller M, Roth P: Immunotherapy for glioblastoma: Concepts and challenges. Curr Opin Neurol 2015; 28: 639-646.
62. Mitchell DA, Batich KA, Gunn MD, et al.: Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519: 366-369.
63. Dai H, Wang Y, Lu X, Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 2016; 108:pii:djv439.
64. Johnson LA, Scholler J, Ohkuri T, et al.: Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7: 275ra222.
65. Brown CE, Badie B, Barish ME, et al.: Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res 2015; 21: 4062-4072.
66. Gan HK, Fichtel L, Lassman AB, et al.: A phase I study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). J Clin Oncol 2014; 32: 5s.